{"id":"cytarabine-or-supportive-care","safety":{"commonSideEffects":[{"rate":"70-90","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"60-80","effect":"Nausea and vomiting"},{"rate":"40-60","effect":"Mucositis"},{"rate":"30-50","effect":"Diarrhea"},{"rate":"10-30","effect":"Hepatotoxicity"},{"rate":"5-25","effect":"Neurotoxicity (at high doses)"},{"rate":"20-40","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cytarabine (ara-C) is a nucleoside analog that mimics cytidine and becomes phosphorylated intracellularly to its active triphosphate form. This active metabolite is incorporated into DNA during synthesis, causing chain termination and inhibition of DNA polymerase. It is primarily effective against rapidly dividing cells, particularly hematopoietic malignancies.","oneSentence":"Cytarabine is a cytidine analog that inhibits DNA synthesis by being incorporated into DNA and blocking chain elongation, thereby killing rapidly dividing cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:23.108Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML)"},{"name":"Acute lymphoblastic leukemia (ALL)"},{"name":"Chronic myeloid leukemia (CML) in blast phase"},{"name":"Lymphoma"}]},"trialDetails":[{"nctId":"NCT07350850","phase":"PHASE2","title":"A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-25","conditions":"PCNSL, Primary Central Nervous System Lymphoma","enrollment":110},{"nctId":"NCT06895473","phase":"PHASE2","title":"Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome","status":"RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-04","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":26},{"nctId":"NCT07244367","phase":"NA","title":"Maintenance Venetoclax in AML Fit Patients","status":"RECRUITING","sponsor":"Sohag University","startDate":"2025-09-01","conditions":"Acute Myeloid Leukaemia (AML)","enrollment":80},{"nctId":"NCT02756962","phase":"PHASE2","title":"Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2016-07-06","conditions":"Acute Myeloid Leukemia","enrollment":107},{"nctId":"NCT03713580","phase":"PHASE1","title":"Venetoclax in Combination With BEAM Conditioning Regimen for ASCT in Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2019-03-12","conditions":"Non-hodgkin Lymphoma","enrollment":25},{"nctId":"NCT02577406","phase":"PHASE3","title":"An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-12-30","conditions":"Leukemia, Myeloid, Isocitrate Dehydrogenase","enrollment":319},{"nctId":"NCT01661881","phase":"PHASE2","title":"Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2012-08-16","conditions":"Mantle Cell Lymphoma","enrollment":23},{"nctId":"NCT02920008","phase":"PHASE3","title":"Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2017-03-16","conditions":"Acute Myeloid Leukemia","enrollment":302},{"nctId":"NCT02088541","phase":"PHASE2","title":"Selinexor (KPT-330) in Older Patients With Relapsed AML","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2014-03","conditions":"Acute Myeloid Leukemia (AML)","enrollment":317},{"nctId":"NCT02067143","phase":"PHASE2","title":"MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2014-05-20","conditions":"Untreated Philadelphia Positive Acute Lymphoblastic Leukemia, De Novo, Secondary","enrollment":204},{"nctId":"NCT00071799","phase":"PHASE3","title":"A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care","status":"COMPLETED","sponsor":"Celgene","startDate":"2003-11-01","conditions":"Myelodysplastic Syndromes","enrollment":358},{"nctId":"NCT00260832","phase":"PHASE3","title":"Trial of Decitabine in Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2005-11","conditions":"Acute Myeloid Leukemia","enrollment":485},{"nctId":"NCT03446638","phase":"NA","title":"iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2019-05","conditions":"Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT01701323","phase":"PHASE1","title":"Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Nohla Therapeutics, Inc.","startDate":"2012-12-10","conditions":"Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia","enrollment":7},{"nctId":"NCT02130869","phase":"PHASE1","title":"A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-10-10","conditions":"Neuroblastoma, Lymphoma, High-risk Tumor","enrollment":8},{"nctId":"NCT01074047","phase":"PHASE3","title":"Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Celgene","startDate":"2010-06-01","conditions":"Acute Myeloid Leukemia","enrollment":488},{"nctId":"NCT00580372","phase":"PHASE2","title":"UARK 89-001 Phase II Study of Intensive \"TOTAL THERAPY\" For Untreated or Minimally Treated Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2002-08","conditions":"Multiple Myeloma","enrollment":231},{"nctId":"NCT02845232","phase":"","title":"Economic Analysis of Blood Product Transfusions According to the Treatment of Acute Myeloid Leukaemia in the Elderly","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2013-03","conditions":"Acute Myeloid Leukemia","enrollment":214},{"nctId":"NCT01147939","phase":"PHASE3","title":"Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)","status":"COMPLETED","sponsor":"Clavis Pharma","startDate":"2010-06","conditions":"Acute Myeloid Leukemia (AML)","enrollment":381},{"nctId":"NCT00466258","phase":"PHASE4","title":"LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2006-10","conditions":"HIV Infections, Diffuse Large B Cell Lymphoma","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":47663,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cytarabine or Supportive Care","genericName":"Cytarabine or Supportive Care","companyName":"Eisai Inc.","companyId":"eisai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cytarabine is a cytidine analog that inhibits DNA synthesis by being incorporated into DNA and blocking chain elongation, thereby killing rapidly dividing cells. Used for Acute myeloid leukemia (AML), Acute lymphoblastic leukemia (ALL), Chronic myeloid leukemia (CML) in blast phase.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}